Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tetiana Perekhrestenko"'
Publikováno v:
The Moldovan Medical Journal, Vol 66, Iss 1, Pp 77-82 (2023)
Background: Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative, monoclonal, indolent hemopathy characterized by pathologically increased synthesis of mature but immunologically dysfunctional B lymphocytes. CLL is considered the pat
Externí odkaz:
https://doaj.org/article/9ccb9584ca804c229eb586d0945585fd
Autor:
Matthew S. Davids, Asher Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kriachok, Hanna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Zvenyslava Maslyak, Andrew Proidakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison Winter, Tamila Lysa, Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass, Mohammad Ahmad, Olena Karpenko, Iurii Osipov, Asit De, Ben Paudyal, Hengbang Wang, Robert Winkler, Nashat Gabrail, Vinod Ganju, Tatiana S. Konstantinova, Olga S. Samoylova, Dajun Yang, Yifan Zhai
Publikováno v:
Blood. 140:2326-2328
Autor:
Carrie Smith, Olga Samoylova, V. E. Ivanov, Bo Huang, Allison M. Winter, Hanna Usenko, Andrew Proidakov, Tetiana Perekhrestenko, Tamila Lysa, Olena Karpenko, Matthew S. Davids, Alan P Skarbnik, Yifan Zhai, Elena Borisenkova, Nashat Y. Gabrail, Boyd Mudenda, Asher Chanan-Khan, Olena Kyselova, Zi Chen, Tatiana Konstantinova, Tanya Siddiqi, Mohammad Ahmad, Tetiana Popovska, Mingyu Li, Iryna Kriachok, Dajun Yang, Olga S. Uspenskaya, Halyna Pylypenko, John M. Pagel, Bulat Bakirov, Les Lukavetsky
Publikováno v:
Blood. 138:1554-1554
Background: BCL-2 inhibition with venetoclax has proved to be highly effective treatment for patients with CLL. However, when administered to patients with CLL who have a high tumor burden, venetoclax is associated with an elevated risk of tumor lysi
Autor:
Tara Baetz, Mamia Zodelava, Christine Burnett, Vasile Musteata, Thomas Strack, Roger J. Waltzman, Tetiana Perekhrestenko, Sarah C. Wilson, Daniel O. Persky, Adolfo Enrique Diaz Duque, Troy H. Guthrie
Publikováno v:
Journal of Clinical Oncology. 38:TPS8074-TPS8074
TPS8074 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable
Autor:
Mamia Zodelava, Daniel O. Persky, Tara Baetz, Tetiana Perekhrestenko, Vasile Musteata, Sarah Wilson, Troy H. Guthrie, Christine Burnett, Adolfo E Diaz, Thomas Strack
Publikováno v:
Blood. 134:5324-5324
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin Lymphoma (NHL) accounting for approximately 30-40% of NHL cases. Approximately 40% of all newly diagnosed DLBCL patients are either refractory or